| Variable | Antipsychotics (all) | Olanzapine monotherapy group | Non-olanzapine antipsychotic group | |||||||||||||||||
| Patients discontinued | Patients continued | p-value | Patients discontinued | Patients continued | p-value | Patients discontinued | Patients continued | p-value | ||||||||||||
| Number |
| 614 | 475 |
| 310 | 268 |
| 304 | 207 |
| ||||||||||
| Gender | Female | 348 | 56.7% | 254 | 53.5% | 0.297F) | 173 | 55.8% | 139 | 51.9% | 0.358F) | 175 | 57.6% | 115 | 55.6% | 0.716F) | ||||
| Male | 266 | 43.3% | 221 | 46.5% | 137 | 44.2% | 129 | 48.1% | 129 | 42.4% | 92 | 44.4% | ||||||||
| Age (yr) | N | 610 | 472 | <0.001S) | 309 | 265 | <0.001S) | 301 | 207 | 0.175S) | ||||||||||
| Mean (SD) | 45.3 | (15.4) | 48.4 | (15.9) | 44.1 | (14.9) | 48.5 | (16.1) | 46.5 | (15.8) | 48.4 | (15.7) | ||||||||
| <20 | 0 | 0.0% | 0 | 0.0% | 0.015M) | 0 | 0.0% | 0 | 0.0% | 0.022M) | 0 | 0.0% | 0 | 0.0% | 0.253M) | |||||
| 20 - 35 | 199 | 32.4% | 117 | 24.6% | 106 | 34.2% | 67 | 25.0% | 93 | 30.6% | 50 | 24.2% | ||||||||
| 36 - 45 | 141 | 23.0% | 101 | 21.3% | 74 | 23.9% | 54 | 20.1% | 67 | 22.0% | 47 | 22.7% | ||||||||
| 46 - 55 | 95 | 15.5% | 79 | 16.6% | 47 | 15.2% | 50 | 18.7% | 48 | 15.8% | 29 | 14.0% | ||||||||
| 56 - 65 | 105 | 17.1% | 101 | 21.3% | 51 | 16.5% | 49 | 18.3% | 54 | 17.8% | 52 | 25.1% | ||||||||
| ³66 | 70 | 11.4% | 74 | 15.6% | 31 | 10.0% | 45 | 16.8% | 39 | 12.8% | 29 | 14.0% | ||||||||
| Unknown | 4 | 0.7% | 3 | 0.6% | 1 | 0.3% | 3 | 1.1% | 3 | 1.0% | 0 | 0.0% | ||||||||
| BMI (kg/m2) | N | 288 | 209 | 0.798S) | 158 | 130 | 0.661S) | 130 | 79 | 0.826S) | ||||||||||
| Mean (SD) | 22.4 | (4.5) | 22.5 | (4.0) | 21.9 | (3.7) | 22.1 | (4.0) | 23.0 | (5.2) | 23.1 | (4.0) | ||||||||
| Onset of illness | Recurrent | 373 | 60.7% | 275 | 57.9% | 0.946F) | 183 | 59.0% | 163 | 60.8% | 0.308F) | 190 | 62.5% | 112 | 54.1% | 0.196F) | ||||
| Initial | 195 | 31.8% | 146 | 30.7% | 103 | 33.2% | 75 | 28.0% | 92 | 30.3% | 71 | 34.3% | ||||||||
| Unknown | 46 | 7.5% | 54 | 11.4% | 24 | 7.7% | 30 | 11.2% | 22 | 7.2% | 24 | 11.6% | ||||||||
| Outpatient or inpatient status | Outpatient | 214 | 34.9% | 231 | 48.6% | <0.001F) | 102 | 32.9% | 119 | 44.4% | 0.005F) | 112 | 36.8% | 112 | 54.1% | <0.001F) | ||||
| Inpatient | 400 | 65.1% | 244 | 51.4% | 208 | 67.1% | 149 | 55.6% | 192 | 63.2% | 95 | 45.9% | ||||||||
| History of schizophrenia (years) | N | 416 | 303 | 0.039S) | 220 | 184 | 0.002S) | 196 | 119 | 0.704S) | ||||||||||
| Mean (SD) | 13.6 | (13.5) | 15.7 | (14.5) | 12.4 | (13.2) | 16.7 | (14.8) | 14.9 | (13.7) | 14.3 | (14.0) | ||||||||
| Prior use of any antipsychotics* | Yes | 206 | 33.6% | 208 | 43.8% | <0.001F) | 94 | 30.3% | 125 | 46.6% | <0.001F) | 112 | 36.8% | 83 | 40.1% | 0.460F) | ||||
| No | 408 | 66.4% | 267 | 56.2% | 216 | 69.7% | 143 | 53.4% | 192 | 63.2% | 124 | 59.9% | ||||||||
| CGI-S Schizophrenia Score** | N | 614 | 475 |
| 0.022 S) | 310 | 268 | 0.022 S) | 304 | 207 | 0.275 S) | |||||||||
| Mean (SD) | 4.9 | (0.9) | 4.9 | (0.9) | 5.0 | (0.9) | 4.8 | (0.9) | 4.8 | (0.8) | 4.7 | (0.9) | ||||||||
| BPRS Total Score** | N | 362 | 314 | 0.140S) | 177 | 177 | 0.649S) | 185 | 137 | 0.126S) | ||||||||||
| Mean (SD) | 58.6 | (14.8) | 60.3 | (15.1) | 59.9 | (15.6) | 60.7 | (15.4) | 57.2 | (13.9) | 59.7 | (14.7) | ||||||||
| BPRS Positive Score** | N | 362 | 314 | 0.860S) | 177 | 177 | 0.650S) | 185 | 137 | 0.950S) | ||||||||||
| Mean (SD) | 16.3 | (4.8) | 16.2 | (4.9) | 16.7 | (5.1) | 16.4 | (4.7) | 16.0 | (4.6) | 16.0 | (5.1) | ||||||||
| BPRS Negative Score** | N | 362 | 314 | <0.001S) | 177 | 177 | <0.001S) | 185 | 137 | 0.039S) | ||||||||||
| Mean (SD) | 10.0 | (3.6) | 11.1 | (3.7) | 9.7 | (3.7) | 11.0 | (3.8) | 10.3 | (3.5) | 11.1 | (3.5) | ||||||||
| BPRS Anxiety/ Depression** | N | 362 | 314 | <0.001S) | 177 | 177 | 0.480S) | 185 | 137 | <0.001S) | ||||||||||
| Mean (SD) | 11.8 | (4.6) | 12.9 | (4.5) | 12.0 | (5.1) | 12.8 | (4.7) | 11.2 | (4.0) | 13.2 | (3.7) | ||||||||